RxDoctor Payments Data

Marni Miltner

Family · Baltimore, MDNPI 1396126371

Payments from drug & device makers

$1,828in general payments, 2019–2025

Across 105 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$450
  • Lilly USA, LLC$279
  • Jazz Pharmaceuticals Inc.$212
  • Boehringer Ingelheim$149
  • AbbVie$140
  • GSK$117
  • plus $480 from 13 others

What the payments were for

  • Food & beverage$1,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,828 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$18,490
Medicare patients
90
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$24,649
Atorvastatin Calcium70$1,095
Losartan Potassium40$621
Pravastatin Sodium29$555
Levothyroxine Sodium38$525
Rosuvastatin Calcium23$505
Gabapentin22$442
Omeprazole29$426
Metoprolol Succinate24$413
Nifedipine ErNifedipine12$302
Oxybutynin Chloride12$285
Amlodipine Besylate35$256
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide14$220
Pantoprazole Sodium18$203
Montelukast Sodium16$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$450$24,64912 claims
Almatica Pharma LLCSertraline Hcl$21$7913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →